Early fecal microbiota composition in children who later develop celiac disease and associated autoimmunity

3 Anniina Rintala MSc^{1,2}; Iiris Riikonen BM¹; Anne Toivonen MD, PhD^{3,4}; Sami Pietilä MSc⁵;

4 Eveliina Munukka PhD¹; Juha-Pekka Pursiheimo PhD⁶; Laura L Elo PhD⁵; Pekka Arikoski MD,

5 PhD⁷; Kristiina Luopajärvi MD, PhD⁸; Ursula Schwab PhD⁹; Matti Uusitupa MD, PhD⁹; Seppo

Heinonen MD, PhD¹⁰; Erkki Savilahti MD, PhD⁸; Erkki Eerola MD, PhD^{2,1}; Jorma Ilonen MD,
PhD^{11,2}

8

⁹ ¹Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland

10 ²Department of Clinical Microbiology and Immunology, Tyks Microbiology and Genetics,

11 Turku University Hospital, Turku, Finland

12 ³Department of Bacteriology and Immunology, University of Helsinki and Laboratory Services

13 (HUSLAB), Division of Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland

- ⁴Department of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern
 Finland, Kuopio, Finland
- ⁵Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku,

17 Finland

⁶Turku Clinical Sequencing Laboratory, University of Turku, Turku, Finland

⁷Department of Pediatrics, Kuopio University Hospital and University of Eastern Finland,
Kuopio, Finland

⁸Children's Hospital, Department of Pediatrics, Helsinki University Hospital and University of
Helsinki, Helsinki, Finland

⁹Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland

24	¹⁰ Department of Obstetrics and Gynecology, Helsinki University Hospital and University of
25	Helsinki, Helsinki, Finland
26	¹¹ Immunogenetics Laboratory, Institute of Biomedicine, University of Turku
27	
28	*Corresponding author:
29	MSc Anniina Rintala, University of Turku, Department of Medical Microbiology and
30	Immunology, Kiinamyllynkatu 13, 20520 Turku, Finland. Tel. +358 50 463 7602; Fax +358
31	2 233 0008; email: anniina.rintala@utu.fi
32	
33	Conflicts of Interest and Source of Funding: The authors declare no conflict of interest. This
34	study was financially supported by Päivikki and Sakari Sohlberg Foundation and Special
35	Research Funds for Kuopio University Hospital.
36	
37	Word count: 5075, including abstract, references, tables and figure captions
38	Figures: 3
39	Tables: 2

40 Abstract

41 **Objectives:** Several studies have reported that the intestinal microbiota composition of celiac 42 disease (CD) patients differs from healthy individuals. The possible role of gut microbiota in the 43 pathogenesis of the disease is, however, not known. Here we aimed to assess the possible 44 differences in early fecal microbiota composition between children that later developed CD and 45 healthy controls matched for age, sex, and HLA risk genotype.

Materials and methods: We used 16S rRNA gene sequencing to examine the fecal microbiota of 27 children with high genetic risk of developing CD. Nine of these children developed the disease by the age of 4 years. Stool samples were collected at the age of 9 and 12 months, before any of the children had developed CD. The fecal microbiota composition of children who later developed the disease was compared with the microbiota of the children who did not have CD or associated autoantibodies at the age of 4 years. Delivery mode, early nutrition, and use of antibiotics were taken into account in the analyses.

53 **Results:** No statistically significant differences in the fecal microbiota composition were found 54 between children who later developed CD (n = 9) and the control children without disease or 55 associated autoantibodies (n = 18).

56 **Conclusions:** Based on our results, the fecal microbiota composition at the age of 9 and 12 57 months is not associated with the development of CD. Our results, however, do not exclude the 58 possibility of duodenal microbiota changes or a later microbiota-related trigger for the disease.

59

Keywords: celiac disease, HLA risk haplotype, fecal microbiota, next-generation sequencing,
16S rRNA gene sequencing

62 Introduction

Celiac disease (CD) is an immune-mediated disorder of the small intestine where gluten induces a mucosal inflammatory reaction. In Finnish population, the prevalence of CD has doubled during the last 30 years [1]. 90% of patients carry HLA-DQ2.5 molecule encoded by *HLA-*DQA1*05 and -DQB1*02 genes, and most of the remaining patients carry HLA-DQ8 molecule encoded by *HLA-DQA1*03* and -DQB1*03:02 genes. Around 30-40% of people of Northern European descent are positive for HLA-DQ2.5 and/or DQ8, demonstrating the role of other etiological factors in the disease development in addition to these major genetic components [2].

Several studies have shown a relation between altered intestinal microbiota composition and CD [3-5]. However, the observed differences may arise from disease process itself, or be dependent on genetic differences. For example, the HLA-DQ2.5 haplotype has been reported to influence the gut microbiota composition of infants [6]. The possible changes and differences in the intestinal microbiota before the onset of CD are unclear.

76

The aim of our study was to screen the fecal microbiota composition of Finnish children genetically at the risk for CD before the onset of the disease. Our objective was to detect the possible differences in the microbiota between children who later developed CD and those who did not. Through this study, we hope to broaden the understanding on the impact of early microbial colonization in the pathogenesis of CD, and to reveal whether early fecal microbiota composition could reflect to the disease risk. To our knowledge, this is the first study so far where the samples have been collected before the onset of CD.

84 Materials and Methods

85 **Study subjects**

86 Stool samples were obtained from 27 Finnish children (recruited at the Kuopio University 87 Hospital and the Kätilöopisto Maternity Hospital in Helsinki) with a high genetic risk for CD 88 participating in a follow-up study [7]. Newborn children were screened for the presence of HLA-DOB1*02 and HLA-DQA1*05 alleles [8] and followed until 3 or 4 years of age by screening for 89 90 tissue transglutaminase autoantibodies (tTGA) [9]. The diagnosis of CD was based on typical 91 histological findings, villous atrophy and crypt hyperplasia, in the duodenal biopsy of small 92 intestine [10]. Nine children (all girls) were diagnosed with duodenal biopsy at the median age of 93 3.5 years (range 2.6 - 4.2 years) after the development of tTGA autoantibodies at the median age 94 of 3 years (18 months to 3 years). They were selected for the study together with 18 control 95 infants, matched by gender and date of birth, remaining negative for tTGA during the follow-up. 96

Stool samples were collected at the age of 9 and 12 months (9mo and 12mo samples, 97 98 respectively). Samples were stored in home freezers (-20°C) for a maximum period of two 99 months, after which they were delivered to the study centers in cool boxes filled with ice bags 100 and stored at -80°C until processing. The 9mo sample from one case infant and 12mo stool 101 sample from one control infant had not been delivered. Data on mode of delivery were obtained 102 from the participating families or obstetric records, and data on nutrition and antibiotics were 103 collected using dietary questionnaires and phone calls at the age of 1-2 weeks, 1.5 months, 3.5 104 months, 6 months and 9 months. After the age of 9 months, the health-related information was 105 collected by general follow-up questionnaires. Written informed consent was obtained from all 106 families. The study plan was accepted by the ethics committee of the Kuopio University107 Hospital.

108

109 **DNA extraction**

Bacterial DNA from ~100 mg of the frozen stool specimens was extracted with a semi-automatic GXT Stool Extraction Kit VER 2.0 (Hain Lifescience GmbH, Nehren, Germany) combined with an additional homogenization by bead-beating in 0.1 mm Glass Bead Tubes (MO BIO

113 Laboratories, Inc., Carlsbad, CA, USA) at 1000 rpm for 3 minutes with MO BIO PowerLyzerTM

114 24 Bench Top Bead-Based Homogenizer (MO BIO Laboratories, Inc., Carlsbad, CA, USA) to

enhance the cell lysis. The DNA concentrations of the DNA extracts were measured with Qubit

dsDNA HS assay kit and Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA, USA). The

117 DNA extracts were stored at -80 °C.

118

119 Fecal microbiota composition analysis

Bacterial profiles of the stool specimens were analyzed with 16S rRNA gene sequencing. The
16S rRNA gene libraries were generated in a single PCR with custom-designed dual-indexed
primers. The approach is described in Supplemental Materials and Methods.

123

124 Data analysis

125 The raw sequence quality was checked with FastQC 126 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and data analysis was performed 127 with Qiime (v. 1.9) pipeline as described previously [11-13]. Sequence reads were filtered with a 128 quality score acceptance rate of 20 or better. Chimeric sequences were filtered using usearch (v. 6.1), and operational taxonomic units (OTUs) were picked using uclust algorithm with 97% sequence similarity. OTUs representing less than 0.05% of the total sequence count were excluded. To minimize the effect of inter-sample variation in the sequencing efficiency, samples were subsampled (rarefied) by random sampling without replacement to the lowest common sequencing depth (134 414 reads). Annotations for the resulting OTUs were derived from GreenGenes database [14].

135

136 All analyses of the 16S rRNA data were made from the randomly subsampled OTU tables. To 137 study the bacterial diversity of the samples, α -diversity metrics were computed and α -rarefaction 138 plots were generated with Qiime. Differences in the Shannon diversity indices were then 139 assessed with JMP Pro 12 (SAS Institute, Inc., Cary, NC, USA), applying non-parametric 140 methods and considering P < 0.05 as statistically significant. Outliers were excluded before the 141 analyses. Taxonomic summary produced by Qiime was visualized as bar charts and statistical 142 differences in the taxonomic richness, i.e. in the OTU abundances, were assessed with non-143 parametric Kruskal-Wallis test. Taxonomic levels phylum and genus were studied, and False 144 Discovery Rate (FDR) adjusted *P*-value < 0.05 was considered as statistically significant. OTUs 145 existing in less than 25% of the samples were excluded before statistical testing. To analyze the 146 differences in the overall bacterial diversity across the samples, weighted UniFrac distance 147 matrices were generated from the randomly subsampled OTU tables and principal coordinate 148 analysis (PCoA) plots were produced. The PCoA plots were visualized with EMPeror. To confirm the visual observations, adonis analyses were performed. Adonis returns an R² value 149 150 showing the amount of variation explained by the grouping variable, and a *P*-value for statistical 151 significance [15].

152

153 Differences in the nutritional variables (duration of breastfeeding, introduction of solid food, and 154 introduction of gluten), and in the number of received antibiotic courses were analyzed with JMP 155 Pro 12 (SAS Institute, Inc.), using non-parametric methods and considering P < 0.05 as 156 statistically significant. To eliminate the mode of birth as a confounding factor, all statistical 157 analyses were first performed for the whole data set (n = 27), and then repeated for the vaginally 158 born infants (n = 24).

160 **Results**

161 The characteristics of the participating children are presented in Table 1. Of the 27 infants in this 162 study, 24 were born by vaginal delivery while three were born by cesarean section (CS). All 163 infants were breastfed at the hospital, but the continuation of breastfeeding varied from seven 164 days to over 18 months (Table 1). The median duration of the breastfeeding was 11 months, yet 165 breastmilk was often supplemented with formula. The median age for solid food introduction 166 was 4.1 months (range 2.0 - 6.2 months), and for gluten introduction 5.7 months (range 4.4 - 7.7 167 months). Infants that were earlier introduced to solid foods were also introduced to gluten earlier 168 (Spearman's correlation 0.679, P < 0.001). No differences in the average breastfeeding duration 169 or in the age of solid food or gluten introduction were observed between the case and control 170 infants (Mann-Whitney U P = 0.5395, P = 0.4712 and P = 0.5539, respectively; Table 2). 171 Control children seemed to be breastfed at the age of gluten introduction more often than the 172 case infants, but the difference was not statistically significant (Pearson's chi-squared test P =173 0.2113; Table 2). Furthermore, no differences were observed in the prescription of antibiotics 174 between the case and control infants (Table 2). In total, 80.8 % of the study subjects had received 175 at least one antibiotic course by the age of 4 years. Exclusion of the infants born by CS did not 176 significantly affect the results regarding the nutritional information or the antibiotics (Table 2).

177

The 16S rRNA gene sequencing of the 52 infant stool specimens resulted in 134k - 330k OTUs per sample (mean 191k, SD 40k), the overall sequence count being 9.9×10^6 OTUs. The average bacterial diversity of the stool samples, represented as median Shannon index values, was 3.32(range 2.66 - 4.32) for 9mo samples and 4.10 (range 3.27 - 4.54) for 12mo samples, showing significant increase in the bacterial diversity between 9 and 12 months (*FDR* = 0.0002). The

183 difference remained significant after the exclusion of the CS infants (P = 0.0014). When all 184 study subjects were included in the analysis, the Shannon indices did not differ between the case 185 and control infants (P = 0.1113 for 9mo samples and P = 0.686 for 12mo samples). The 186 "observed species" metric of Qiime confirmed these findings, representing little difference 187 between the case and control infants (Fig. 1a and 1b) but a clear difference between the 9mo and 188 12mo samples (Fig. 1c). However, when only the vaginally born infants were studied, the 189 Shannon indices in the 9mo samples tended to be higher in the cases than in the controls (P =190 0.049). In the 12mo samples, the difference between the case and control infants remained 191 insignificant after exclusion of the infants born by CS (P = 0.302).

192

193 The average phylum and genus level bacterial composition of the case and control samples, i.e. 194 the average relative bacterial OTU abundances, are represented as bar charts in Fig. 2. Minor 195 differences can be visually seen in the bacterial taxonomy between the case and control infants in 196 both 9mo and 12mo samples (Fig. 2a and 2b). However, Qiime reported no statistically 197 significant differences in the bacterial composition between the case and control infants when the 198 microbial abundances at phylum and genus levels were assessed. Further, no differences were 199 observed in Bacteroides-Prevotella or Bacteroides-Bifidobacterium ratios between the case and 200 control infants in neither 9mo nor 12mo samples (P = 0.201 and P = 0.388 for Bacteroides-201 *Prevotella* and P = 0.955 and P = 0.572 for *Bacteroides-Bifidobacterium*, respectively). In 202 principal coordinate analysis (PCoA) plot, where individual samples with similar microbiota 203 composition cluster together, no differences could be observed between the case and control 204 infants (Fig 3a and b). Further, adonis analysis confirmed that no significant differences between 205 the cases and controls occurred in neither 9mo nor 12mo samples (P = 0.808 and P = 0.696,

respectively). One 9mo control sample had a significantly deviating bacterial profile (Fig. 3a) with more than 50% of the bacteria being *Enterobacteriaceae*, but as this had no effect on the results of the statistical analyses and did not significantly affect the bar chart figures, the sample was not excluded from the final analyses. The results regarding the fecal microbiota composition between the case and control infants remained unaltered when excluding the infants born by cesarean section, with only minor differences in the *P* values (results not shown).

212

The results concerning the effect of age, delivery mode and nutritional variables on the fecal microbiota composition are presented in Supplemental Results. Briefly, the bacterial composition differed significantly between the 9mo and 12mo samples (Fig. 2b and 3c) and between the infants born vaginally or by CS. Further, the duration of breastfeeding correlated with several bacterial genera. However, the fecal microbiota composition did not significantly differ between the children that had been breastfed during gluten introduction and the ones that had not (*FDR* > 0.1 for all bacterial phyla and genera in both 9mo and 12mo samples).

220 **Discussion**

221 Previous studies have reported that the gut microbiota composition of CD patients differs from 222 healthy individuals [3,16]. It is, however, unclear whether the altered gut microbiota has a role in 223 the pathogenesis of CD or merely is a consequence of the disease [17]. The HLA-DQ2.5 224 haplotype has been reported to influence the intestinal bacterial community of infants [6], but most of these children do not develop CD. In the Finnish population, less than 10% of the DO2.5 225 226 positive subjects develop the disease. We compared the early fecal microbiota composition 227 between children with the risk genotype who later developed CD and genetically susceptible 228 children who did not develop the disease or associated autoantibodies during the follow-up. 229 Based on the 10% lifetime risk and identification of already 6.5% of children with tTGA (cases 230 included) in the whole follow-up group, we don't expect many new cases among the selected 231 tTGA negative controls. Follow-up studies also suggest that the appearance of new CD 232 associated autoantibodies is leveling off after 3 to 4 years of age [18].

233

234 Stool samples were collected at the age of 9 and 12 months and analyzed with 16S rRNA gene 235 sequencing enabling the detection and relative quantification of the bacterial taxa present in the 236 samples. Previous studies have reported differences in the levels of *Bacteroides*, *Clostridium* and 237 Staphylococcus genera, alongside with the Bacteroides-Prevotella ratio between the CD patients 238 and healthy controls [16]. In addition, one certain *Bacteroides* species, *Bacteroides dorei*, has 239 been associated with active CD [19]. In this present study, the abundance of *Bacteroides dorei* 240 was not assessed, as the species level identification by 16S rRNA gene sequencing is uncertain 241 [11,20]. At the genus level, however, neither *Bacteroides* abundance nor the *Bacteroides*-242 Prevotella ratio differed between the case and control infants. Further, the abundance of 243 *Clostridium* genera did not differ between the case and control infants, and *Staphylococcus* genus 244 was completely undetectable in this sample cohort. Altogether, in this study, no statistically 245 significant differences in the fecal microbial diversity or composition were found between the 246 children who later developed CD and the ones who did not. Thereby, our results suggest that 247 early fecal microbiota composition would not be associated with the pathogenesis of CD, while 248 the previous findings concerning the differences in the gut microbiota between CD patients and 249 healthy individuals might have risen for example from dietary changes after the disease onset or 250 from the disrupted gut homeostasis due to altered mucosal immune responses [21,22]. To some 251 extent, the findings regarding the gut microbiota composition in CD may also be methodology 252 dependent. Further, as the 16S rRNA sequencing only reveals the microbial composition of the 253 stool samples, functional profiles of the microbiota remain uncovered. In order to study the 254 functionality of the gut microbes, metaproteomic or metabolomic analyses should be performed 255 [23,24]. It has been previously shown that the metabolic activity of the gut microbiota in CD 256 children differs from healthy individuals both before and after the implementation of gluten-free 257 diet [25,26].

258

Even though the results of this study suggest that the early fecal microbiota composition may not predict the development of CD, this does not exclude the possibility of a microbiota-related trigger for the disease. As e.g. dietary changes, antibiotics and infections can disrupt the intestinal homeostasis [27], it remains possible that some external trigger could later disastrously disturb the gut microbiota balance, leading to the onset of the disease [28]. In fact, one hypothesis for the CD onset is that intestinal infections could interfere the intestinal homeostasis and lead to increased intestinal permeability, i.e. leaky gut (for review, see [29]), which could then allow the absorption of undigested gliadin molecules that initiate the immune processes leading to the disease [30]. However, few studies have investigated the role of specific infectious agents in the development of the disease, yet in some studies an increased prevalence of CD has been associated with repeated early infections [31,32]. In this study, use of antibiotics was taken into account in the analyses, but the possible impact of early viral infections was not assessed.

271

272 In addition to sudden external triggers, gradual unfavorable progression of the gut microbiota 273 may also lead to leaky gut and the activation of the inflammatory pathways [29]. For example, 274 epidemiological studies have reported that children born by CS have an increased risk for CD 275 compared to the vaginally delivered infants [33-35]. In this study cohort, the mode of delivery 276 had a significant effect on the fecal microbiota composition, but due to the limited number of CS 277 children, no conclusions regarding the role of delivery mode on CD risk could be drawn. 278 However, based on the results of this study, the individuals who develop CD do not already in 279 the early infancy have a distinct fecal microbiota composition compared to other infants with 280 risk-HLA-haplotype, suggesting that the onset of CD is more likely a consequence of a strong 281 external trigger rather than gradual development due to a peculiarly vulnerable gut microbiota. 282 However, feces may not be the most optimal sample material for CD studies, as CD primarily 283 affects the small intestine and fecal microbiota inadequately reflects the duodenal microbiota 284 [4,36]. Thus, this study does not rule out the possibility of small intestinal microbiota changes 285 prior to the onset of the disease. On the other hand, the duodenal mucosal homeostasis was not 286 assessed, as studies on the mucosal host-microbial crosstalk and the possibility of unfavorable 287 immune functions would have required the collection of duodenal biopsies. Previous studies

regarding the role of duodenal microbiota in CD-linked mucosal immune responses remain
rather inconclusive [22,37,38], making this an extremely interesting area for future research.

290

291 The possible protective role of breastfeeding against CD onset has been analyzed in several 292 studies, and the gradual gluten introduction during ongoing breastfeeding has been suggested to 293 protect against the disease [39,40]. Some recent studies, however, have not been able to confirm 294 these results [39-42]. In this study, the average duration of breastfeeding did not differ between 295 the case and control children, but the controls tended to be more likely breastfed during the 296 gluten introduction. The duration of breastfeeding correlated with several bacterial genera, of 297 which especially Lactobacillus and Bifidobacterium have been previously linked to positive 298 health outcomes (for review, see [43]). However, no difference in the abundance of 299 Lactobacillus or Bifidobacterium could be observed between the infants who later developed CD 300 and the infants who did not. Further, no differences in the fecal microbiota composition were 301 seen between the infants that were breastfed during gluten introduction and the ones who did not, 302 suggesting that even though breastfeeding might induce changes in the gut microbiota, the 303 possible protective role of breastfeeding against CD might not be related to gut microbiota. 304 However, due to the limited number of infants not breastfed during the gluten introduction in this 305 study, these results are merely indicative.

306

307 Conclusions

308 Our results indicate that the fecal microbiota composition at the age of 9 and 12 months is not 309 associated with the development of CD. Our results do not exclude the possibility of duodenal 310 microbiota differences or a later microbiota-related trigger for the disease, but suggest that the

311	infants developing CD do not originally have distinct fecal microbiota composition compared to
312	individuals that possess the risk-HLA-haplotype but do not develop the disease.
313	

314 Acknowledgements

315 Anne Björk and Sirpa Nolvi are acknowledged for organizing the sample collection and for 316 collecting the nutritional and health data. Heidi Isokääntä and Minna Lamppu are warmly 317 thanked for excellent technical assistance in the sample processing.

318

319 **Declaration of interest**

320 The authors declare no conflicts of interest.

321 **References**

[1] Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time.
Aliment Pharmacol Ther. 2007;26(9):1217-1225.

324 [2] Dieli-Crimi R, Cénit MC, Núñez C. The genetics of celiac disease: A comprehensive review
 325 of clinical implications. J Autoimmun. 2015;64:26-41.

- [3] Nadal I, Donant E, Ribes-Koninckx C, et al. Imbalance in the composition of the duodenal
 microbiota of children with coeliac disease. J Med Microbiol. 2007;56(12):1669-1674.
- [4] Collado MC, Donat E, Ribes-Koninckx C, et al. Specific duodenal and faecal bacterial
 groups associated with paediatric coeliac disease. J Clin Pathol. 2009;62(3):264-269.
- 330 [5] Collado MC, Donat E, Ribes-Koninckx C, et al. Imbalances in faecal and duodenal
- Bifidobacterium species composition in active and non-active coeliac disease. BMC
- 332 microbiology. 2008;8(1):232.

[6] Olivares M, Neef A, Castillejo G, et al. The HLA-DQ2 genotype selects for early intestinal

- microbiota composition in infants at high risk of developing coeliac disease. Gut.
- 335 2015;64(3):406-417.
- [7] Lammi A, Arikoski P, Hakulinen A, et al. Development of gliadin-specific immune
 responses in children with HLA-associated genetic risk for celiac disease. Scand J Gastroenterol.
 2016;51(2):168-177.
- [8] Lundin KE, Scott H, Hansen T, et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201)
- restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med.
 1993;178(1):187-196.
- [9] Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the
 autoantigen of celiac disease. Nat Med. 1997;3(7):797-801.
- 344 [10] Marsh MN. Gluten, major histocompatibility complex, and the small intestine: a molecular
- 345 and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue').
- 346 Gastroenterology. 1992;102(1):330-354.
- [11] Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput
 community sequencing data. Nature methods. 2010;7(5):335-336.
- 349 [12] Kuczynski J, Stombaugh J, Walters WA, et al. Using QIIME to analyze 16S rRNA gene
- 350 sequences from microbial communities. Current protocols in microbiology. 2012:1E. 5.1-1E.

351 5.20.

- [13] Bokulich NA, Subramanian S, Faith JJ, et al. Quality-filtering vastly improves diversity
 estimates from Illumina amplicon sequencing. Nature methods. 2013;10(1):57-59.
- [14] DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA
 gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72(7):50695072.
- [15] Navas-Molina JA, Peralta-Sanchez JM, Gonzalez A, et al. Advancing our understanding of
 the human microbiome using QIIME. Methods Enzymol. 2013;531:371-444.
- [16] Collado MC, Calabuig M, Sanz Y. Differences between the fecal microbiota of coeliac
 infants and healthy controls. Curr Issues Intestinal Microbiol. 2007;8(1):9.
- 361 [17] Cenit MC, Codoner-Franch P, Sanz Y. Gut Microbiota and Risk of Developing Celiac
- 362 Disease. J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics
- 363 & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-
- 364 15, 2015:S148-S152.
- [18] Liu E, Lee H, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA
 haplotype and country. N Engl J Med. 2014;371(1):42-49.
- [19] Sanchez E, Donat E, Ribes-Koninckx C, et al. Intestinal Bacteroides species associated with
 coeliac disease. J Clin Pathol. 2010;63(12):1105-1111.
- 369 [20] Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a
- depth of millions of sequences per sample. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:45164522.
- [21] De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin coated bacteria associated with coeliac disease in children. BMC microbiology. 2010;10(1):63.
- [22] Cheng J, Kalliomäki M, Heilig HG, et al. Duodenal microbiota composition and mucosal
 homeostasis in pediatric celiac disease. BMC gastroenterology. 2013;13(1):113.
- [23] Matysik S, Le Roy CI, Liebisch G, et al. Metabolomics of fecal samples: a practical
 consideration. Trends Food Sci Technol. 2016;57:244-255.
- 378 [24] Wilmes P, Heintz-Buschart A, Bond PL. A decade of metaproteomics: where we stand and379 what the future holds. Proteomics. 2015;15(20):3409-3417.
- [25] Tjellström B, Stenhammar L, Högberg L, et al. Gut microflora associated characteristics in
 children with celiac disease. Am J Gastroenterol. 2005;100(12):2784-2788.
- 382 [26] Nistal E, Caminero A, Vivas S, et al. Differences in faecal bacteria populations and faecal
- bacteria metabolism in healthy adults and celiac disease patients. Biochimie. 2012;94(8):1724-
- 384 1729.

- [27] Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the
 human gut microbiota. Nature. 2012;489(7415):220-230.
- [28] Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nature Reviews
 Immunology. 2016;16(6):341-352.
- [29] Marasco G, Di Biase AR, Schiumerini R, et al. Gut microbiota and celiac disease. Dig Dis
 Sci. 2016;61(6):1461-1472.
- 391 [30] Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731-1743.
- [31] Myléus A, Hernell O, Gothefors L, et al. Early infections are associated with increased risk
 for celiac disease: an incident case-referent study. BMC pediatrics. 2012;12(1):194.
- 394 [32] Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of 395 celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol.
- 396 2006;101(10):2333-2340.
- [33] Decker E, Engelmann G, Findeisen A, et al. Cesarean delivery is associated with celiac
 disease but not inflammatory bowel disease in children. Pediatrics. 2010;125(6):e1433-40.
- [34] Cho CE, Norman M. Cesarean section and development of the immune system in theoffspring. Obstet Gynecol. 2013;208(4):249-254.
- 401 [35] Mårild K, Stephansson O, Montgomery S, et al. Pregnancy outcome and risk of celiac
 402 disease in offspring: a nationwide case-control study. Gastroenterology. 2012;142(1):39-45. e3.
- 403 [36] Stearns JC, Lynch MD, Senadheera DB, et al. Bacterial biogeography of the human
 404 digestive tract. Scientific reports. 2011;1:170.
- 405 [37] Nistal E, Caminero A, Herrán AR, et al. Differences of small intestinal bacteria populations
- in adults and children with/without celiac disease: effect of age, gluten diet, and disease.
 Inflamm Bowel Dis. 2011;18(4):649-656.
- 408 [38] McLean MH, Dieguez D,Jr, Miller LM, et al. Does the microbiota play a role in the 409 pathogenesis of autoimmune diseases?. Gut. 2015;64(2):332-341.
- 410 [39] Ivarsson A, Myleus A, Norstrom F, et al. Prevalence of childhood celiac disease and 411 changes in infant feeding. Pediatrics. 2013;131(3):e687-94.
- [40] Ivarsson A, Hernell O, Stenlund H, et al. Breast-feeding protects against celiac disease. Am
 J Clin Nutr. 2002;75(5):914-921.
- 414 [41] Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at
- 415 high risk for celiac disease. N Engl J Med. 2014;2014(371):1304-1315.

- 416 [42] Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the
- 417 risk of celiac disease in children. N Engl J Med. 2014;371(14):1295-1303.
- 418 [43] de Sousa Moraes LF, Grzeskowiak LM, de Sales Teixeira TF, et al. Intestinal microbiota
- 419 and probiotics in celiac disease. Clin Microbiol Rev. 2014;27(3):482-489.

420

422 Appendices

- 423 Supplemental Materials and Methods
- 424 Supplemental Results

Tables

ID	Case/control	Mode of delivery	Solid food introduction (months)	Gluten introduction (months)	Duration of breastfeeding (months)
1	case	vaginal	6.24	6.24	> 18.0
2	control	vaginal	4.27	7.66	6.0
3	control	vaginal	3.02	4.50	0.23
4	case	vaginal	3.98	4.40	1.0
5	control	vaginal	4.63	5.55	N/A
6	control	vaginal	3.88	5.75	11.0
7	case	vaginal	4.01	5.03	2.5
8	control	vaginal	4.60	5.13	13.0
9	control	vaginal	4.04	5.52	6.0
10	case	vaginal	4.04	5.62	N/A
11	control	vaginal	4.17	5.85	13.0
12	control	vaginal	3.84	5.36	12.0
13	case	vaginal	2.00	4.50	0.33
14	control	vaginal	4.07	5.26	6.0
15	control	vaginal	4.50	5.26	10.0
16	case	vaginal	5.55	6.31	12.0
17	control	cesarean section	3.94	6.05	7.0
18	control	vaginal	5.16	5.85	12.0
19	case	vaginal	5.36	6.67	14.0
20	control	vaginal	5.59	5.95	18.0
21	control	vaginal	5.55	6.44	7.5
22	case	vaginal	5.42	6.08	16.0
23	control	cesarean section	3.81	5.22	7.5
24	control	vaginal	4.14	5.65	16.0
25	case	cesarean section	4.07	6.28	> 18.0
26	control	vaginal	4.01	5.65	11.0
27	control	vaginal	3.48	5.00	5.0

Table 1: Background information of the study subjects

Tuble 2. Huttitional information and antibiotic courses of the stady subjects									
	All infants in this study (n = 27)			Vaginally born infants (n = 24)					
	Cases $(n = 9)$	Controls (n = 18)	Р	Cases $(n = 8)$	Controls (n = 16)	Р			
Average duration of breastfeeding (months)	10.2 (SD 7.69)	9.48 (SD 4.43)	0.5395 ^M	9.12 (SD 7.59)	9.78 (SD 4.64)	0.9155 ^M			
Average age for solid food introduction (months)	4.52 (SD 1.27)	4.26 (SD 0.66)	0.4712 ^M	4.57 (SD 1.34)	4.31 (SD 0.69)	0.8301 ^M			
Average age for gluten introduction (months)	5.68 (SD 0.84)	5.65 (SD 0.67)	0.5539 ^M	5.61 (SD 0.86)	5.65 (SD 0.69)	0.6025 ^M			
Breast feeding during gluten introduction (% of subjects)	66,7 %	87.5 %	0.2113 ^p	62.5 %	85.7 %	0.2113 ^p			
Antibiotic courses before 9 months (% of subjects)	37.5 %	35.3 %	0.9146 ^p	28.6 %	26.67 %	0.9256 ^p			
Antibiotic courses before 12 months (% of subjects)	42.9 %	47.1 %	0.8511 ^p	33.3 %	40.0 %	0.7763 ^p			
Antibiotic courses before 4 years (% of subjects)	87.5 %	77.8 %	0.5615 ^p	85.7 %	75.0 %	0.5665 ^p			

Table 2: Nutritional information and antibiotic courses of the study subjects

^MMann-Whitney U test, ^PPearson's chi-squared test

430 Figure Legends


Figure 1: Bacterial diversity of the study samples, represented as observed different OTUs per sequences. At the age of nine months, case infants tend to have a slightly more diverse fecal microbiota than the controls (a), but this difference is statistically significant only when the infants born by cesarean section are excluded from the analysis. At the age of 12 months, no differences can be seen (b). By contrast, a clear difference can be observed in the bacterial diversity between the 9mo and 12mo samples (c). The rarefaction level is 134 414 reads per sample.


438

Figure 2: The average bacterial composition of the study samples. No significant differences can be visually observed in the phylum level bacterial composition neither between the case and control infants nor between the 9mo and 12mo samples (a). Differences in the genus level bacterial composition are more prominent; 9mo and 12mo samples differ clearly from each other, and in the 9mo samples, minor differences can be observed between the case and control infants (b). The rarefaction level is 134 414 reads per sample.

445

Figure 3: Principal Coordinate Analysis (PCoA) of the study samples. Case and control
infants do not cluster separately in the PCoA in either 9mo (a) or 12mo (b) samples.
Furthermore, 9mo and 12mo samples do not form clearly separate clusters in the PCoA (c). The
rarefaction level is 134 414 reads per sample.





p Firmicutes;c Bacilli;o Lactobacillales;Other;Other

f Enterococcaceae:g Enterococcus

f Lactobacillaceae;g Lactobacillus

f Streptococcaceae;g Lactococcus

f Streptococcaceae:g Streptococcus

f Turicibacteraceae;g Turicibacter

O Clostridiales:Other:Other

case

f Ruminococcaceae;g Anaerotruncus

f Ruminococcaceae;q Faecalibacterium

f Ruminococcaceae:Other

f Ruminococcaceae;q



- c TM7-3;o CW040;f ;g
- f_Verrucomicrobiaceae;g_Akkermansia

